Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

DeepDyve requires Javascript to function. Please enable Javascript on your browser to continue.

Immune Tolerance for the Treatment of Factor VIII Inhibitors ‐ Twenty Years' ‘Bonn Protocol’

Brackmann, H. H.; Oldenburg, J.; Schwaab, R.

Vox Sanguinis , Volume 70 – Jan 1, 1996

Read Article

Download PDF

Share Full Text for Free

6 pages

Loading next page...

References (14)

G. Bray, ED Gomperts, S. Courter, R. Gruppo, EM Gordon, M. Manco‐Johnson, A. Shapiro, E. Scheibel, GIII White, M. Lee (1994)
A multicenter study of recombinant factor VIII (Recombinate): Safety, efficacy and inhibitor risk in previously untreated patients with haemophilia A
, 83
Brackmann (1977)
Massive factor VIII infusion in a haemophiliac with factor VIII inhibitor, high response
Lancet, ii
HH Brackmann (1982)
Activated Prothrombin Complex Concentrates
E. Tuddenham, R. Schwaab, J. Seehafer, D. Millar, J. Gitschier, M. Higuchi, S. Bidichandani, J. Connor, L. Hoyer, A. Yoshioka, I. Peake, K. Olek, H. Kazazian, J. Lavergne, F. Giannelli, S. Antonarakis, D. Cooper (1994)
Haemophilia A: database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene, second edition.
Nucleic acids research, 22 22
H. Brackmann, J. Gormsen (1977)
MASSIVE FACTOR-VIII INFUSION IN HÆMOPHILIAC WITH FACTOR-VIII INHIBITOR, HIGH RESPONDER
The Lancet, 310
JM Lusher, S. Arkin, CF Abildgaard, RS Schwartz (1993)
Kogenate Previously Untreated Patient Study Group: Recombinant factor VIII for the treatment of previously untreated patients with haemophilia A. Safety, efficacy. and the development of inhibitors
, 328
S. Ehrenforth, W. Kreuz, R. Linde, M. Funk, T. Güngör, B. Krackhardt, B. Kornhuber, I. Scharrer (1992)
Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs
The Lancet, 339
J. Lusher, S. Arkin, C. Abildgaard, R. Schwartz (1993)
Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group.
The New England journal of medicine, 328 7
E. Kurczynski, J. Penner (1974)
Activated prothrombin concentrate for patients with factor VIII inhibitors.
The New England journal of medicine, 291 4
J. Lusher, S. Arkin, C. Abilgaard, R. Schwartz (1993)
Recombinant Factor VIII for the Treatment of Previously Untreated Patients with Hemophilia A: Safety, Efficacy, and Development of Inhibitors
Survey of Anesthesiology, 37
G. Bray, E. Gomperts, S. Courter, R. Gruppo, EM Gordon, M. Manco‐Johnson, A. Shapiro, E. Scheibel, G. White, M. Lee (1994)
A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group.
Blood, 83 9
(1982)
The treatment of inhibitors against factor Vl l l by continuous treatment with factor Vl l l and activated prothrombin complex concentrates ; in Mariani G . Russo MA
(1994)
cy and inhibitor risk in previously untreated patients with haemophilia A
Immune Tolerance for the Treatment of FVlll Inhibitors

Publisher: Wiley
Copyright: Copyright © 1996 Wiley Subscription Services
ISSN: 0042-9007
eISSN: 1423-0410
DOI: 10.1111/j.1423-0410.1996.tb01346.x
Publisher site: See Article on Publisher Site

There are no references for this article.